Fed. Circ. Must Rethink Upholding Cancer Drug IP, Zydus Says
A judge in Delaware federal court flubbed his analysis when deciding two patents covering Genzyme Corp.'s cancer medication Mozobil weren't obvious, and the Federal Circuit failed to correct the error, Zydus...To view the full article, register now.
Already a subscriber? Click here to view full article